Retrospective Analysis of Molecular Markers in Endometrial Cancer: Single Center Experience

Clinical and Experimental Obstetrics & Gynecology Pub Date : 2024-02-21 DOI:10.31083/j.ceog5102043

Cem Yagmur Ozdemir, D. Arıoz, Nayif Çiçekli, Mariam Chkhikvadze, F. Bilir, Cigdem Ozdemir, Hacer Demir, Evrim Suna Arıkan Soylemez

{"title":"Retrospective Analysis of Molecular Markers in Endometrial Cancer: Single Center Experience","authors":"Cem Yagmur Ozdemir, D. Arıoz, Nayif Çiçekli, Mariam Chkhikvadze, F. Bilir, Cigdem Ozdemir, Hacer Demir, Evrim Suna Arıkan Soylemez","doi":"10.31083/j.ceog5102043","DOIUrl":null,"url":null,"abstract":"Background : To emphasize the effect of molecular markers on prognosis in endometrial cancer, in addition to the International Federation of Gynecology and Obstetrics (FIGO) 2009 classification. Methods : The records of 160 patients with endometrial cancer between 2008 and 2022 were retrospectively reviewed. Staging was done according to FIGO 2009 criteria. Patients were divided into 4 groups according to molecular classification. If one had polymerase epsilon ( POLE ) mutation, the patient was included in POLE ultramutated (POLEmut) group. In case of intakt POLE , but abnormal staining of mismatch repair (MMR), the group was diagnosed as mismatch repair defciency (MMRd). If there was only p53 abnormal results detected, that group was p53-abnormal (p53mut). If no mutation at all, that group was categorized as non-specific molecular profile (NSMP). The Kaplan-Meier method was used to evaluate overall survival and progression-free survival. Survival rates were compared for molecular markers. Results : According to the molecular analysis, 4 patients (2.5%) were classifed as POLEmut group, 53 patients (33.1%) in the MMRd group, 18 patients (11.3%) had p53mut, and 85 patients (53.1%) into the NSMP group. 5-year overall survival was 79.4%, 5-year progression-free survival was 90%. 5-year overall survival was 75% in POLEmut group, 84.9% in MMRd group, 38.9% in p53mut group and 84.7% in NSMP group ( p = 0.001). 5-year progression-free survival was 100% in POLEmut group, 96.2% in MMRd group, 77.8% in p53mut group and 88.2% in NSMP group ( p = 0.082). Conclusion : Our study shows the prognostic value of the molecular endometrial cancer classification. Patients with p53mut have a poor progression-free survival, POLEmut endometrial cancer have a good prognosis. In this study, we wanted to demonstrate the importance of molecular markers in endometrium cancer and their contribution to prognosis.","PeriodicalId":505527,"journal":{"name":"Clinical and Experimental Obstetrics & Gynecology","volume":"10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Obstetrics & Gynecology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31083/j.ceog5102043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background : To emphasize the effect of molecular markers on prognosis in endometrial cancer, in addition to the International Federation of Gynecology and Obstetrics (FIGO) 2009 classification. Methods : The records of 160 patients with endometrial cancer between 2008 and 2022 were retrospectively reviewed. Staging was done according to FIGO 2009 criteria. Patients were divided into 4 groups according to molecular classification. If one had polymerase epsilon ( POLE ) mutation, the patient was included in POLE ultramutated (POLEmut) group. In case of intakt POLE , but abnormal staining of mismatch repair (MMR), the group was diagnosed as mismatch repair defciency (MMRd). If there was only p53 abnormal results detected, that group was p53-abnormal (p53mut). If no mutation at all, that group was categorized as non-specific molecular profile (NSMP). The Kaplan-Meier method was used to evaluate overall survival and progression-free survival. Survival rates were compared for molecular markers. Results : According to the molecular analysis, 4 patients (2.5%) were classifed as POLEmut group, 53 patients (33.1%) in the MMRd group, 18 patients (11.3%) had p53mut, and 85 patients (53.1%) into the NSMP group. 5-year overall survival was 79.4%, 5-year progression-free survival was 90%. 5-year overall survival was 75% in POLEmut group, 84.9% in MMRd group, 38.9% in p53mut group and 84.7% in NSMP group ( p = 0.001). 5-year progression-free survival was 100% in POLEmut group, 96.2% in MMRd group, 77.8% in p53mut group and 88.2% in NSMP group ( p = 0.082). Conclusion : Our study shows the prognostic value of the molecular endometrial cancer classification. Patients with p53mut have a poor progression-free survival, POLEmut endometrial cancer have a good prognosis. In this study, we wanted to demonstrate the importance of molecular markers in endometrium cancer and their contribution to prognosis.

查看原文本刊更多论文

子宫内膜癌分子标记物的回顾性分析：单中心经验

背景：除了国际妇产科联盟（FIGO）2009 年的分类外，强调分子标记对子宫内膜癌预后的影响。方法：回顾性分析 2008 年至 2022 年间 160 例子宫内膜癌患者的病历。根据 FIGO 2009 标准进行分期。根据分子分类将患者分为 4 组。如果其中一人有聚合酶ε（POLE）突变，则被归入POLE超突变（POLEmut）组。如果POLE突变但错配修复（MMR）染色异常，则被诊断为错配修复缺陷（MMRd）组。如果只检测到 p53 异常，则该组为 p53 异常组（p53mut）。如果完全没有突变，则该组被归类为非特异性分子特征（NSMP）。采用 Kaplan-Meier 法评估总生存期和无进展生存期。比较分子标记物的存活率。结果：根据分子分析，4例患者（2.5%）被归入POLEmut组，53例患者（33.1%）被归入MMRd组，18例患者（11.3%）被归入p53mut组，85例患者（53.1%）被归入NSMP组。5年总生存率为79.4%，5年无进展生存率为90%。POLEmut组的5年总生存率为75%，MMRd组为84.9%，p53mut组为38.9%，NSMP组为84.7%（P = 0.001）。POLEmut组的5年无进展生存率为100%，MMRd组为96.2%，p53mut组为77.8%，NSMP组为88.2% ( p = 0.082)。结论：我们的研究显示了子宫内膜癌分子分类的预后价值。p53突变患者的无进展生存期较差，而POLEmut子宫内膜癌患者的预后较好。在这项研究中，我们希望证明分子标记物在子宫内膜癌中的重要性及其对预后的贡献。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Experimental Obstetrics & Gynecology

自引率

0.00%

发文量